Echocardiography showed a good ejection fraction (70%) and no myocarditis.On electromyography of the right deltoid, biceps brachii, and iliopsoas, fibrillation potentials were seen only in the biceps muscle. with no relevant family history of neuromuscular disorders was found to have a lung nodule on a regular medical checkup in 2016. Subsequently, a diagnosis of lung adenocarcinoma with brain and bone metastases was made by pulmonologists. The tumor proportion score of the programmed cell death-ligand 1 (PD-L1) expression was 85%, so he was started on pembrolizumab in July 2017 (day 1). On day 23, he was found to have diplopia, and his CK level had increased from 55 to 600 U/L. He was admitted to our hospital on day 30 with stable vital signs. On a physical examination, he had diplopia and ptosis in the left eye with daily fluctuation. He had no easy fatigability or weakness in the limbs and trunk. On laboratory testing, his creatine kinase (CK) level was 7,311 U/L, aldolase 16.5 IU/L, aspartate aminotransferase (AST) 172 U/L, alanine aminotransferase (ALT) 74 U/L, lactate dehydrogenase (LDH) 631 U/L, creatinine 1.17 mg/dL, C-reactive protein (CRP) 0.68 mg/dL, erythrocyte sedimentation rate (ESR) 34 mm/h, and D-dimer 1.4 g/mL. His thyroid function was within the normal range [thyroid Catechin stimulating hormone (TSH) 1.75 IU/mL, FT3 2.61 pg/mL, FT4 1.05 ng/dL]. Rheumatoid factor, antinuclear antibody, anti-double stranded DNA (dsDNA) antibody, anti-ribonucleoprotein (RNP) antibody, anti-histidyl transfer RNA synthetase (Jo-1) antibody, anti-aminoacyl transfer RNA synthetase (ARS) antibody, anti-mitochondrial M2 (M2) antibody, anti-signal recognition particle (SRP) antibody, and anti-3-hydroxy-3-methylglutary-coenzyme A reductase (HMGCR) antibody were all negative. Anti-acetylcholine receptor (AChR) antibody, anti-muscle-specific kinase (MuSK) antibody, and anti-voltage-gated potassium channel Kv1.4 antibody were also negative, but anti-titin antibody was positive, leading to the diagnosis of MG, although both the repetitive nerve stimulation test (right accessory nerve, axillary nerve, median nerve, and ulnar nerve) and the edrophonium test were negative. The ice pack test was not evaluated. Arterial blood gas analyses and spirometry showed no evidence of respiratory insufficiency. Echocardiography showed a good ejection fraction (70%) and no myocarditis.On electromyography of the right deltoid, biceps brachii, and iliopsoas, fibrillation potentials were seen only in the biceps muscle. Low-amplitude and short-duration motor unit potentials were recorded in all Catechin muscles, indicating myogenic changes. Magnetic resonance imaging of the thigh muscles showed no evidence of myopathy. A muscle biopsy from the left biceps brachii showed scattered necrotic and regenerating muscle fibers with minimal reactive mononuclear cell infiltration (Fig. 1A, B). Tubular aggregates were seen in some fibers (Fig. 1C, D). On immunohistochemistry, major histocompatibility complex (MHC)-I was mildly expressed in fibers in some areas (Fig. 1E), and membrane attack complex (MAC) was deposited on the sarcolemma of some non-necrotic fibers, in addition to the cytoplasm of necrotic fibers (Fig. Catechin 1F). Open in a separate window Figure 1. Pathological features of necrotizing myopathy. A, B: Hematoxylin and Eosin staining demonstrates necrosis and regeneration of muscle fibers and necrotizing myopathy with inflammatory cell infiltration only around necrotic fibers. A: scale bar 100 m, B: scale bar 50 m. C: Gomori trichrome staining, D: dihydronicotinamide adenine dinucleotide (NADH) staining. IL1B Tubular aggregates can be seen. C, D: scale bar 20 m. E: Major histocompatibility complex (MHC)-I staining demonstrates light staining of muscle fibers. Scale bar 100 m. F: Membrane attack complex (MAC) staining demonstrates the deposition of necrotic fibers, with light deposition of non-necrotic fibers. Scale bar 50 m. Based on the above results, a diagnosis of ocular MG (Myasthenia Gravis Foundation of America I) with anti-titin antibody Catechin and necrotizing myopathy with tubular aggregates was made. The Quantitative MG score was 6 points (ptosis and diplopia: 3 and 3 points, respectively). The patient was given an ascending-dose regimen of prednisolone that increased by 5 mg every 5 days to a total of 20 mg. He initially had exacerbation of ptosis and opthalmoplegia with diplopia. The CK level showed a trend toward reduction, but it remained high. Therefore, Catechin steroid pulse therapy (methylprednisolone 1 g/day 3 times) was given. The CK level then normalized promptly, and his symptoms improved gradually. All abnormal neurological.